Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy
Recruiting · NCT05905328 · Registry updated 2026-08-31Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of CTO1681 for the Prevention and Treatment of CRS in Patients Receiving CAR T-Cell Therapy | Inflammation, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Shock, Systemic Inflammatory Response Syndrome, cytokine release syndrome | Recruiting | Phase 1 / Phase 2 | 2026-08-31 | NCT05905328 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| CytoAgents, Inc. | 1 |
| National Cancer Institute (NCI) | 3015 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beth Israel Deaconess Medical Center | Boston | United States | 462 |
| Duke Cancer Institute | Durham | United States | 9 |
| Fred Hutchinson Cancer Center | Seattle | United States | 250 |
| Georgia Cancer Center at Augusta University | Augusta | United States | 23 |
| University of California, Irvine - Chao Family Comprehensive Cancer Center | Orange | United States | 1 |
| University of Pittsburgh Medical Center | Pittsburgh | United States | 63 |